De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Cencora Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Cencora is de winst gegroeid met een gemiddeld jaarlijks percentage van 27.5%, terwijl de Healthcare industrie de winst jaarlijks groeide met 6.2%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 10% per jaar. Het rendement op eigen vermogen van Cencora is 175.5%, en het heeft een nettomarge van 0.7%.
Belangrijke informatie
27.5%
Groei van de winst
28.0%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 8.5% |
| Inkomstengroei | 10.0% |
| Rendement op eigen vermogen | 175.5% |
| Nettomarge | 0.7% |
| Volgende winstupdate | 06 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly
Sep 18
Cencora: Credentials To Die For, But Underlying Issues Make Case For 'Hold' Rating
Sep 18Market Participants Recognise Cencora, Inc.'s (NYSE:COR) Earnings
Jul 16Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning
Jun 30Are Investors Undervaluing Cencora, Inc. (NYSE:COR) By 43%?
Jun 28Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly
Jun 09Do Cencora's (NYSE:COR) Earnings Warrant Your Attention?
May 21Investors Interested In Cencora, Inc.'s (NYSE:COR) Earnings
Apr 05Cencora Remains Chronically Undervalued, With Material Growth Potential
Mar 25Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price
Mar 18Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly
Feb 25Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Feb 07Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price
Jan 05Cencora: Continued Economic Value On The Table Across All Investment Horizons
Jan 04A Look At The Fair Value Of Cencora, Inc. (NYSE:COR)
Dec 15Cencora (NYSE:COR) Is Paying Out A Larger Dividend Than Last Year
Nov 05Is Cencora (NYSE:COR) A Risky Investment?
Nov 03Cencora: New Name, Same Old Economic Leverage, Reiterate Buy
Oct 18AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 34% Below Their Intrinsic Value Estimate
Aug 01AmerisourceBergen: Great Company, Wrong Price (Rating Downgrade)
Jul 28We Think AmerisourceBergen (NYSE:ABC) Can Stay On Top Of Its Debt
Jun 19Is AmerisourceBergen Corporation (NYSE:ABC) Trading At A 28% Discount?
May 01Here's Why We Think AmerisourceBergen (NYSE:ABC) Is Well Worth Watching
Apr 10AmerisourceBergen (NYSE:ABC) Has A Pretty Healthy Balance Sheet
Mar 02AmerisourceBergen declares $0.485 dividend
Feb 01AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 25% Below Their Intrinsic Value Estimate
Jan 28AmerisourceBergen partners with pharmaceutical company Civica
Jan 23Opbrengsten en kosten
Hoe Cencora geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 283,831 | 1,856 | 5,565 | 0 |
| 31 Mar 24 | 276,537 | 1,852 | 5,486 | 0 |
| 31 Dec 23 | 271,579 | 1,867 | 5,418 | 0 |
| 30 Sep 23 | 262,173 | 1,745 | 5,310 | 0 |
| 30 Jun 23 | 254,425 | 1,689 | 5,180 | 0 |
| 31 Mar 23 | 247,543 | 1,617 | 5,088 | 0 |
| 31 Dec 22 | 241,805 | 1,729 | 4,970 | 0 |
| 30 Sep 22 | 238,587 | 1,699 | 4,849 | 0 |
| 30 Jun 22 | 236,325 | 1,842 | 4,801 | 0 |
| 31 Mar 22 | 229,666 | 1,727 | 4,502 | 0 |
| 31 Dec 21 | 221,101 | 1,614 | 4,029 | 0 |
| 30 Sep 21 | 213,989 | 1,540 | 3,594 | 0 |
| 30 Jun 21 | 204,321 | -3,744 | 3,062 | 0 |
| 31 Mar 21 | 196,282 | -3,747 | 2,815 | 0 |
| 31 Dec 20 | 194,546 | -3,222 | 2,779 | 0 |
| 30 Sep 20 | 189,894 | -3,409 | 2,767 | 0 |
| 30 Jun 20 | 186,287 | 1,570 | 2,768 | 0 |
| 31 Mar 20 | 186,159 | 1,582 | 2,758 | 0 |
| 31 Dec 19 | 182,061 | 649 | 2,693 | 0 |
| 30 Sep 19 | 179,589 | 855 | 2,664 | 0 |
| 30 Jun 19 | 177,248 | 956 | 2,599 | 0 |
| 31 Mar 19 | 175,151 | 930 | 2,569 | 0 |
| 31 Dec 18 | 172,866 | 1,190 | 2,558 | 0 |
| 30 Sep 18 | 167,940 | 1,658 | 2,460 | 0 |
| 30 Jun 18 | 163,763 | 1,081 | 2,363 | 0 |
| 31 Mar 18 | 159,327 | 855 | 2,262 | 0 |
| 31 Dec 17 | 155,441 | 979 | 2,167 | 0 |
| 30 Sep 17 | 153,144 | 364 | 2,129 | 0 |
| 30 Jun 17 | 151,584 | 855 | 2,098 | 0 |
| 31 Mar 17 | 149,759 | 1,154 | 2,089 | 0 |
| 31 Dec 16 | 148,310 | 1,346 | 2,087 | 0 |
| 30 Sep 16 | 146,850 | 1,428 | 2,091 | 0 |
| 30 Jun 16 | 144,759 | 1,643 | 2,107 | 0 |
| 31 Mar 16 | 142,111 | 1,508 | 2,093 | 0 |
| 31 Dec 15 | 139,082 | 391 | 2,016 | 0 |
| 30 Sep 15 | 135,962 | -138 | 1,908 | 0 |
| 30 Jun 15 | 132,080 | -431 | 1,821 | 0 |
| 31 Mar 15 | 128,195 | -658 | 1,706 | 0 |
| 31 Dec 14 | 123,981 | 35 | 1,640 | 0 |
| 30 Sep 14 | 119,569 | 282 | 1,581 | 0 |
| 30 Jun 14 | 112,449 | 267 | 1,486 | 0 |
| 31 Mar 14 | 104,008 | 344 | 1,430 | 0 |
| 31 Dec 13 | 96,076 | 368 | 1,377 | 0 |
Kwaliteitswinsten: COR heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (0.7%) COR } zijn lager dan vorig jaar (0.7%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van COR is de afgelopen 5 jaar aanzienlijk gegroeid met 27.5% per jaar.
Versnelling van de groei: De winstgroei van COR over het afgelopen jaar ( 9.9% ) ligt onder het 5-jarig gemiddelde ( 27.5% per jaar).
Winst versus industrie: De winstgroei COR over het afgelopen jaar ( 9.9% ) overtrof de Healthcare -sector 8%.
Rendement op eigen vermogen
Hoge ROE: Hoewel het rendement op eigen vermogen ( 175.46% ) van COR uitstekend is, is deze metriek vertekend vanwege hun hoge schuldenniveau.